July 24th 2024
The PDUFA goal date for TLX007-CDx is March 24, 2025.
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Approval sought for TLX007-CDx in prostate cancer
May 28th 2024“If approved by the FDA, this new product will have a significant impact on prostate cancer patients, physicians, and their caregivers by helping to eliminate the inequity of access to PSMA-PET agents, and increase the ability to accurately diagnose cancer early, reducing the cost of care, and increasing the probability of patients’ survival," says Mike Crosby.
Dr. Leonardo Kayat Bittencourt discusses advantages of prostate MRI
February 25th 2024"We have information today from a number of well-powered, well-designed prospective studies showing that performing an MRI before the decision to do the first biopsy adds value," says Leonardo Kayat Bittencourt, MD, PhD.
Investigators evaluate PI-RADS upgrading rules for prostate cancer
February 16th 2024"What we found was that the obedience to the upgrading criteria of PI-RADS as they are today resulted in a better overall outcome for all the patients that were included in the study," says Leonardo Kayat Bittencourt, MD, PhD.
Post-Void MRIs may enhance understanding of midline radiotracer activity on PSMA PET/CT
February 9th 2024PSMA uptake in the prostatic midline is often linked with urine stagnation in the prostatic urethra and can lead to misinterpretation on PSMA-PET/CT,” the authors wrote. “Using post-void MRIs may help reduce false positives.”